Helical tomotherapy for solitary lung tumor: feasibility study and dosimetric evaluation of treatment plans

Technology in Cancer Research & Treatment
Natsuo TomitaHidetoshi Shimizu

Abstract

The purpose of this study is to evaluate the feasibility of and treatment plans for helical tomotherapy (HT) for solitary lung tumors. Nine patients with stage IA non-small-cell lung cancer (NSCLC) and three patients with solitary lung metastasis were treated with HT. All patients were immobilized with the BodyFIX system, and the target volume shown on computed tomography in the 3 respiration phases were superimposed onto the 3-dimensional radiation treatment planning system to represent the internal target motion. All patients were treated with 54-60 Gy in 12 fractions over 8 to 13 days. The median follow-up time was 14 months (range: 3-16 months). The overall response rate was 92%. The local control rate at 1 year was 100% with no difference between NSCLC and metastasis. Of 12 patients, one patient experienced Grade 2 radiation pneumonitis (RP), and the other patient with severe interstitial pneumonia and emphysema experienced Grade 5 RP. The mean lung dose (MLD) and the dose-volume histogram (DVH) for the normal lung volumes were converted into normalized total dose with an alpha/beta ratio of 3 Gy. The DVH of the normal lung volumes demonstrated that the mean volumes of V(10), V(30), V(50), and V(70) were 40.4 +/- 9.4%, 21....Continue Reading

References

Aug 12, 1999·Physics in Medicine and Biology·J M KapatoesT R Mackie
Oct 13, 2001·International Journal of Radiation Oncology, Biology, Physics·M UematsuS Kusano
Apr 18, 2002·International Journal of Radiation Oncology, Biology, Physics·Yasushi NagataMasahiro Hiraoka
Aug 8, 2002·Physics in Medicine and Biology·Thomas BortfeldSteve B Jiang
Sep 20, 2005·International Journal of Radiation Oncology, Biology, Physics·Yasushi NagataMasahiro Hiraoka
Feb 24, 2006·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Emilie T SoissonMinesh P Mehta
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert TimmermanJames Fletcher
Dec 22, 2006·Physics in Medicine and Biology·Brian KanagakiKe Sheng
Mar 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert D TimmermanLei Xing
Jul 19, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Masahiro Hiraoka, Satoshi Ishikura
Sep 18, 2007·International Journal of Radiation Oncology, Biology, Physics·Alonso N GutiérrezMinesh P Mehta
Nov 30, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Peter FritzErich Stoelben
Nov 4, 2008·International Journal of Radiation Oncology, Biology, Physics·Matthias GuckenbergerMichael Flentje
Dec 3, 2008·Technology in Cancer Research & Treatment·N TomitaY Shibamoto
Dec 17, 2008·International Journal of Radiation Oncology, Biology, Physics·Ik Jae LeeJaeho Cho
Mar 27, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Gerben R BorstJan-Jakob Sonke
May 8, 2009·International Journal of Radiation Oncology, Biology, Physics·Ji Yoon KimKi Joon Kim
May 12, 2009·International Journal of Radiation Oncology, Biology, Physics·Atsuya TakedaAtsushi Kubo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.